Zulresso – pharmaceutical daily

July 2, 2019 Off

ZULRESSO Launched by Sage Therapeutics, 11th FDA-approved drug to use Ligand’s Captisol technology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy.

March 20, 2019 Off

Sage Therapeutics gets approval for Zulresso, first new drug to treat postpartum depression

By Dino Mustafić

Sage Therapeutics got clearance from the FDA has approved Zulresso (brexanolone) injection for the treatment of postpartum depression (PPD), and is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth.